AbCellera Biologics (ABCL) Cost of Revenue (2020 - 2025)

AbCellera Biologics has reported Cost of Revenue for 6 years, with the latest figure at $2.9 million in Q3 2025.

• For the quarter ending Q3 2025, Cost of Revenue fell 7.3% year-over-year to $2.9 million; the trailing twelve-month figure through Sep 2025 stood at -$878000.0 (up 39.2% YoY), and the FY2022 full-year result was $11.3 million, up 63.03% from the prior year.
• Cost of Revenue for Q3 2025 stood at $2.9 million, down from $3.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $44.6 million in Q1 2022, with the low at -$53.6 million in Q4 2022.
• Historically, Cost of Revenue has averaged $786000.0 across 5 years, with a median of $3.0 million in 2025.
• The largest YoY upside for Cost of Revenue was 1630.02% in 2022 against a maximum downside of 3035.41% in 2022.
• AbCellera Biologics' Cost of Revenue stood at $1.8 million in 2021, then slumped by 3035.41% to -$53.6 million in 2022, then surged by 79.34% to -$11.1 million in 2023, then grew by 13.04% to -$9.6 million in 2024, then soared by 130.16% to $2.9 million in 2025.
• The last three Cost of Revenue figures came in at $2.9 million (Q3 2025), $3.0 million (Q2 2025), and $2.8 million (Q1 2025), per Business Quant data.